EGFR-mutated lung cancer: a paradigm of molecular oncology

Cited by (198)

Items 101–198 of 198

1. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations
   Zebo Jiang, Jun Huang, Chun Xie, Xia Li, Liping Liu, Jiaxi He, HUI PAN, Liyan Huang, Xing‐Xing Fan, Xiaojun Yao et al. · 2016 · Oncology Reports
2. Pulmonary Administration: Strengthening the Value of Therapeutic Proximity
   Mafalda Videira, Jordi Llop, Carolina Sousa, Bruna Kreutzer, Unai Cossío, Ben Forbes, Isabel Vieira, Nuno Gil, Beatriz Silva Lima · 2020 · Frontiers in Medicine
3. Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy
   Donghai Li · 2012 · International Journal of Oncology
4. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR
   Jinsong Li, Huayun Deng, Meichun Hu, Yuanzhang Fang, Amanda Vaughn, Xiaopan Cai, Leqin Xu, Wei Wan, Zhenxi Li, Shijie Chen et al. · 2015 · Oncotarget
5. Cariprazine, A Dopamine D2/D3 Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
   Noor A. Hussein, Charles R. Ashby, Haneen A. Amawi, Angelique Nyinawabera, Atul Vij, Vishwa Mohini Khare, Chandrabose Karthikeyan, Amit Kumar Tiwari · 2018 · Cancers
6. Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer
   Nicoletta Cordani, Daniele Nova, Luca Sala, Maria Ida Abbate, Francesca Colonese, Diego Luigi Cortinovis, Stefania Canova · 2024 · International Journal of Molecular Sciences
7. Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer
   Brian S Bogdanowicz, Matthew A. Hoch, Megan E. Hartranft · 2016 · Journal of Oncology Pharmacy Practice
8. Ligand-based virtual screening, molecular docking, QSAR and pharmacophore analysis of quercetin-associated potential novel analogs against epidermal growth factor receptor
   Uma Devi Bommu, Kranthi Kumar Konidala, Pabbaraju Neeraja, Suneetha Yeguvapalli · 2017 · Journal of Receptors and Signal Transduction
9. Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients
   Laksmi Wulandari, Gatot Soegiarto, Anna Febriani, Farah Fatma Wati, Sahrun · 2020 · Indian Journal of Surgical Oncology
10. Docking and molecular dynamics simulation study of EGFR1 with EGF-like peptides to understand molecular interactions
    D. Sudhakar, Kalaiarasan Ponnusamy, Naidu Subbarao · 2016 · Molecular BioSystems
11. USP8: a novel therapeutic target for Cushing’s disease
    Fangfang Jian, Yanan Cao, Liuguan Bian, Qingfang Sun · 2015 · Endocrine
12. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC
    Dong Min Kim, Mi Jin Kim, Jai-Hee Moon, Eun Young Lee, Jun Ki Hong, Seul Lee, Dong‐In Koh, Yae Seong Ryu, Seungmi Kim, Soo-A Jung et al. · 2020 · Biochemical and Biophysical Research Communications
13. Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Ondřej Fiala, Miloš Pešek, Jindřich Fínek, Lucie Benešová, Zbyněk Bortlíček, Marek Minárik · 2013 · Neoplasma
14. Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI–Mediated Anticancer Activity in NSCLC
    Zheng Yang, Kin Iong Chan, Hang Fai Kwok, Kin Yip Tam · 2019 · Translational Oncology
15. Comparative experimental/theoretical studies on the EGFR dimerization under the effect of EGF/EGF analogues binding: Highlighting the importance of EGF/EGFR interactions at site III interface
    Masomeh Mehrabi, Hamid Mahdiuni, Hassan Rasouli, Kamran Mansouri, Mohsen Shahlaei, Reza Khodarahmi‬ · 2018 · International Journal of Biological Macromolecules
16. Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
    Ji Eun Shin, Hyun Ae Jung, Sehhoon Park, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Byoung Yong Shim · 2025 · Scientific Reports
17. Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.
    Swaroop Revannasiddaiah, Priyanka Thakur, Bhaskar Bhardwaj, Sridhar Papaiah Susheela, Irappa Madabhavi · 2014 · Europe PMC (PubMed Central)
18. Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib
    Guanzhong Yan, Ruyong Yao, Dongfang Tang, Tong Qiu, Yi Shen, Wenjie Jiao, Nan Ge, Yunpeng Xuan, Yongjie Wang · 2014 · Medical Oncology
19. The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response
    Ana Hipólito, Cindy Mendes, Jacinta Serpa · 2020 · Advances in experimental medicine and biology
20. Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma
    Suliman Boulos, Min Chul Park, Marian Zeibak, Shen Yun Foo, Yoon Kyung Jeon, Young Tae Kim, Alex Motzik, Sagi Tshori, Tamar Hamburger, Sung‐Hoon Kim et al. · 2017 · Oncotarget
21. MOLECULAR BASIS OF MODERN TARGETED THERAPY FOR SQUAMOUS CELL CARCINOMA OF THE TONGUE AND ORAL MUCOSA WITH MONOCLONAL ANTIBODIES
    Аза Ахметовна Льянова, Liubov Yu Vladimirova, Elena Mikhaylovna Frantsiyants, Denis S. Kutilin, Marina A. Engibaryan · 2017 · Malignant tumours
22. Molecular mechanisms contributing to resistance to tyrosine kinase-targeted therapy for non-small cell lung cancer.
    Fariz Nurwidya, Akiko Murakami, Fumiyuki Takahashi, Kazuhisa Takahashi · 2012 · Europe PMC (PubMed Central)
23. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
    Ondřej Fiala, Miloš Pešek, Jindřich Fínek, Lucie Benešová, Zbyněk Bortlíček, Marek Minárik · 2013 · PubMed
24. Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors.
    Yunhua Xu, Qunxiong Pan, Chongren Wang, HE Chun-ya, Zijian Su, Xiaowei Guo, Jian Zhang, Min Kong, Shaoying Ke, Jianhua Zhang et al. · 2014 · Europe PMC (PubMed Central)
25. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation
    Dominik Thomas Koch, Anja Pickhard, Lena Gebel, Anna Maria Stefanie Buchberger, Murat Baş, Carolin Mogler, Rudolf Reiter, Guido Piontek, Markus Wirth · 2017 · Oncotarget
26. Femoral metastatic pathological fractures, impending and actual fractures – A patient survival study
    Oded Hershkovich, Mojahed Sakhnini, Gal Barkay, Boaz Liberman, Alon Friedlander, Raphael Lotan · 2023 · Surgical Oncology
27. Transforming Growth Factor β Signaling Overcomes Dasatinib Resistance in Lung Cancer
    Edna R. Gordián, Jiannong Li, Yuri Pevzner, Melanie Mediavilla-Varela, Kimberly A. Luddy, Kim C. Ohaegbulam, Kenyon G. Daniel, Eric B. Haura, Teresita Muñoz-Antonia · 2014 · PLoS ONE
28. Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer
    Àlvaro Quintanal-Villalonga, Mariló Mediano, Irene Ferrer, Ricardo Melendez, Andrés Carranza-Carranza, Rocío Aguilar Suárez, Amancio Carnero, Sonia Molina‐Pinelo, Luis G Paz-Ares · 2018 · Oncotarget
29. OmicsNet: Integration of Multi-Omics Data using Path Analysis in Multilayer Networks
    Murodzhon Akhmedov, Alberto J. Arribas, Roberto Montemanni, Francesco Bertoni, Ivo Kwee · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
30. Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine.
    Elnaz Salmani-Javan, Mahdi Farhoudi Sefidan Jadid, Nosratollah Zarghami · 2024 · PubMed Central
31. Update in Lung Cancer and Oncological Disorders 2010
    Balázs Halmos, Charles A. Powell · 2011 · American Journal of Respiratory and Critical Care Medicine
32. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)
    Andrés Felipe Cardona, Camila Ordóñez‐Reyes, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Zyanya Lucía Zatarain-Barrón, Gonzalo Recondo, Leonardo Rojas, Luis Corrales, Claudio Marcelo Martin, Feliciano Barrón et al. · 2021 · JCO Precision Oncology
33. Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases
    Lili Zhang, Lu Yang, Binxu Sun, Yixiao Deng, Jie Yang, Dongfang Wu, Fanming Kong · 2022 · Frontiers in Oncology
34. Advances in Therapeutic Approaches Using RNA Interference as a Gene Silencing Tool
    Burçin Tezcanlı Kaymaz, Buket Kosov · 2013 · Advanced Techniques in Biology & Medicine
35. Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
    Martina Ruglioni, Iacopo Petrini, Stefania Crucitta, Andrea Sbrana, Giovanna Irene Luculli, Leila Sadeghi Gol, Carola Forte, Antonio Chella, Christian Diego Rolfo, Romano Danesi et al. · 2024 · Translational Oncology
36. Characterization of Somatic Mutations in Malaysian Luminal Breast Cancer
    Yock Ping Chow, Ryia Illani Mohd Yunos, Isabelle Rose, Norlia Abdullah, Rohaizak Muhammad, Shahrun Niza Abdullah Suhaimi, Saladina Jaszle, Norshahidah Mahamad Nadzir, Nurul‐Syakima Ab Mutalib, Rahman Jamal · 2018 · Progress In Microbes & Molecular Biology
37. Integrated Tissue and Blood miRNA Expression Profiles Identify Novel Biomarkers for Accurate Non-Invasive Diagnosis of Breast Cancer: Preliminary Results and Future Clinical Implications
    Fei Su, Ziyu Gao, Yueyang Liu, Guiqin Zhou, Ying Cui, Chao Deng, Yuyu Liu, Yihao Zhang, Xiaoyan Ma, Yongxia Wang et al. · 2022 · Genes
38. The future of lung cancer therapy: Striding beyond conventional EGFR and ALK treatments
    Sandhya Iyer, Rambaksh Prajapati, Aarthi Ramesh, Madhura Basavalingegowda, Seema P. Todur, Shubham Kavishwar, Rajeev Vijaykumar, R. Naik, Padmaj Sudhakar Kulkarni, Amit Bhatt et al. · 2019 · Molecular and Clinical Oncology
39. KRAS-driven miR-29b expression is required for tumor suppressor gene silencing
    Shilpa Thakur, Charles Brenner · 2017 · Oncotarget
40. The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients
    Antoîne Italiano, Othilie Gautier, Jules Dupont, Tarek Assi, Lama Dawi, Littisha Lawrance, Alexandre Bône, Ghina Jardali, Aurélie Choucair, Samy Ammari et al. · 2025 · European Journal of Cancer
41. Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
    Olivia A. Sagan, Anna Rothstein, Bhaghyasree Jambunathan, Mersiha Hadziahmetovic, Anita Antoniolli, M. Hammad Rashid · 2023 · Frontiers in Oncology
42. Anterior Gradient 2 is Correlated with EGFR Mutation in Lung Adenocarcinoma Tissues
    Sodai Narumi, Yasuhiro Miki, Shuko Hata, Masahito Ebina, Mikiyoshi Saito, Kazushige Mori, Makoto Kobayashi, Takashi Suzuki, Erina Iwabuchi, Ikuro Sato et al. · 2015 · The International Journal of Biological Markers
43. Extracellular inhibitors can attenuate tumorigenic Wnt pathway activity in adenomatous polyposis coli mutants: Predictions of a validated mathematical model
    Gili Hochman, Karin Halevi-Tobias, Yuri Kogan, Zvia Agur · 2017 · PLoS ONE
44. Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease
    Mohammed E. Abo‐El Fetoh, Maha M. Abdel‐Fattah, Hassan Afify, Laila A. A. Ramadan, Wafaa R. Mohamed · 2023 · Egyptian Pharmaceutical Journal
45. Identifying the Impact of Inframe Insertions and Deletions on Protein Function in Cancer
    Hanadi M. Baeissa, Frances M. G. Pearl · 2019 · Journal of Computational Biology
46. Clinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma
    Xin-Ke Zhang, Tao Qin, Yuanyuan Zhao, Xue Hou, Wenfeng Fang, Shaodong Hong, Ting Zhou, Zhihuang Hu, Yunpeng Yang, Yu‐Xiang Ma et al. · 2015 · OncoTargets and Therapy
47. Functional genomic screening to enhance oncolytic virotherapy
    Douglas J. Mahoney, David F. Stojdl · 2012 · British Journal of Cancer
48. Association of EGFR gene polymorphism in head and neck cancer patients with tobacco and alcohol consuming habits
    Nagalakshmi, Kaiser Jamil, P. Usha Rani · 2013 · Biology and medicine
49. Erlotinib in the treatment of advanced squamous cell NSCLC
    Ondřej Fiala, Miloš Pešek, Jindřich Fínek, Jana Krejčí, Libor Havel, Michal Hrnčiarik, František Salajka, Zbyněk Bortlíček, Lucie Benešová, Marek Minárik · 2013 · Neoplasma
50. Oncología personalizada: principales biomarcadores en el pronóstico y tratamiento de tumores sólidos
    Marta Molina Romero, Emilio José Laserna Mendieta, Gema María Varó Sánchez, María Concepción Alonso‐Cerezo, María Orera Clemente · 2018 · Revista del Laboratorio Clínico
51. Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology
    Ho-Sung Lee, In-Hee Lee, Kyungrae Kang, Sang‐In Park, Tae-Wook Kwon, Dae-Yeon Lee · 2021 · Evidence-based Complementary and Alternative Medicine
52. Anticancer Activity of Salvia miltiorrhiza and Its Secondary Metabolites
    Ching‐Fen Wu, Thomas Efferth · 2017 · Springer eBooks
53. Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Comprehensive Review
    Lukas Delasos, Khaled Aref Hassan · 2026 · JCO Oncology Practice
54. Structural Features of Quercetin Derivatives by Using Pharmaco-phore Modeling Approach
    Nixon Mendez, Md. Afroz Alam · 2016 · Open Pharmaceutical Sciences Journal
55. Molecular Docking, Molecular Dynamics Simulation, and Analysis of EGFR-derived Peptides against the EGF
    Samaneh Ghasemali, Safar Farajnia, Atefeh Nazari, Nasrin Bargahi, Mina Mohammadinasr · 2023 · Letters in Drug Design & Discovery
56. EGFR mutations in patients with advanced NSCLC
    Ondřej Fiala, Miloš Pešek, Jindřich Fínek, Frantisek Bruha, Zbyněk Bortlíček, Jana Krejčí, Lucie Benešová, Marek Minárik · 2012 · Lung Cancer
57. Twenty‐One Novel EGFR Kinase Domain variants in Patients with Nonsmall Cell Lung Cancer
    Marcia Anahí Hasenahuer, Gustavo D. Parisi, Marien Gautier, Alberto Lazarowski, Guillermo Federico Bramuglia, Marı́a Silvina Fornasari · 2015 · Annals of Human Genetics
58. Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer
    Elizabeth S. Waxman, Frank V. Fossella · 2016 · Journal of the Advanced Practitioner in Oncology
59. Medicinal Chemistry Case History: Osimertinib (AZD9291)
    Richard A. Ward, M. Raymond V. Finlay · 2016 · Elsevier eBooks
60. Pulmonary adenocarcinoma with epidermal growth factor receptor‐mutations in asbestos exposed non‐smokers: A case series
    Richard L. Kradin, John Iafrate, David C. Christiani · 2017 · American Journal of Industrial Medicine
61. Intracellular Signaling Network as a Prime Chemotherapy Target of Green Tea Catechin, (–)-Epigallocatechin-3-gallate
    Brahma Nand Singh, Sharmila Shankar, Rakesh K. Srivastava · 2012 · Springer eBooks
62. Lower Respiratory Tract
    Consolato Maria Sergi · 2020 · Springer eBooks
63. Targeted drug conjugates and molecular mechanisms in overcoming lung cancer drug resistance
    Lu Ye, Shuang Xiang, Rou Xue, Yihao Zhang, Yanan Wang, Xinrong Xiong, Chuan Qin, Song Duan · 2025 · Discover Oncology
64. Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies
    Rita Khoury, Chris Raffoul, Colette Hanna, Khalil Saleh, Annoir Shayya, Meriana Nahouli, Hady Ghanem · 2026 · International Journal of Molecular Sciences
65. Development of Targeted Agents and Companion Diagnostics
    B. Gérard, Marie-Christine Bétard, Bradley Smith, Madlyn Denyer · 2012 · Drug Information Journal
66. Personalized Medicine: Development of a Predictive Computational Model for Personalized Therapeutic Interventions
    Nelofar Kureshi · 2013 · DalSpace (Dalhousie University)
67. To Treat or Not to Treat: When Is Adjuvant EGFR TKI Therapy Appropriate?
    Ramsey Asmar, Balázs Halmos · 2015 · American Journal of Hematology / Oncology®
68. Retreatment with Erlotinib of a Patient with Metastatic NSCLC Harboring EGFR Mutation: A Case Report
    Ondřej Fiala, Miloš Pešek, Jindřich Fínek, Gabriela Krákorová, Lucie Benešová, Marek Minárik · 2014 · Tumori Journal
69. Cerric ammonium nitrate catalyzed eco-friendly green synthesis of chitosan Schiff base using PEG-400 as an anticancer agent against gastric cancer cells via inhibiting EGFR
    Wei Geng, Xinwei Feng, Chunfeng Li, Sifeng Ni · 2024 · Bulletin of the Chemical Society of Ethiopia
70. Pharmacogenomics in Lung Cancer
    George R. Simon, Rafael Rosell, David R. Gandara · 2018 · Elsevier eBooks
71. Population-based statistical inference for temporal sequence of somatic mutations in cancer genomes
    Je‐Keun Rhee, Tae‐Min Kim · 2018 · BMC Medical Genomics
72. Anticancer activity of cepharanthine on non-small cell lung cancer cells
    Yaowaluck Detpichai, Piyanuch Wonganan · 2020
73. Selective and Specific Activation of Rab5 during Endocytosis of Receptor Tyrosine Kinases
    Ivan Jozic · 2013
74. Resistance to Tyrosine Kinase Inhibitors in EGFR-mutant of Non-Small Cell Lung Cancer
    Akiko Murakami, Fumiyuki Takahashi, Faisal Yunus, Kazuhisa Takahashi · 2012 · Journal Of The Indonesian Medical Association
75. Výskyt mutací genu EGFR u pacientů s NSCLC v České republice
    Ondřej Fiala, Monika Šatánková, Juraj Kultan, Miloš Pešek, Jana Skřičková, Vı́tězslav Kolek, Jindřich Fínek, Zuzana Zbožínková, Zbyněk Bortlíček · 2014
76. Pharmacogenomics in Molecular Oncology
    Soya Sisy Sam, Gregory J. Tsongalis · 2014 · Springer eBooks
77. Characterization of mTOR Inhibition and Autophagy Inhibition in Non-Small Cell Lung Cancer
    Rebecca R. Britt · 2014
78. Biomarkers in lung cancer
    T. Nwizu, Ravi Salgia · 2011
79. Proteomics for Cancer: Approaches and Challenges
    Surekha Mahesh Zingde · 2019 · Springer eBooks
80. Proportion of Mutation of Epidermal Growth Factor Receptor (EGFR) Genes from Tissue Biopsy and Liquid Biopsy ctDNA in Lung Adenocarcinoma
    Hendra Taufik, Noni Novisari Soeroso, Setia Putra Tarigan, Erna Mutiara · 2020 · Jurnal Respirologi Indonesia
81. Cáncer de pulmón, una revisión sobre el conocimiento actual, métodos diagnósticos y perspectivas terapéuticas
    Edgar Amorín Kajatt · 2014 · Revista Peruana de Medicina Experimental y Salud Pública
82. Unlocking effective transgene expression potential in gene therapy with viral vectors
    Nur Shuhaidatul Sarmiza Abdul Halim, Noor Hanis Abu Halim, Lelamekala Vengidasan, Norashikin Zakaria, Ida Shazrina Ismail, Badrul Hisham Yahaya · 2021 · Biomedical Research and Therapy
83. Targeted cancer radioimaging and radiotherapy and the development of tumor-avid molecules using phage display
    Austin Prater · 2021
84. Physical Sciences in Cancer: Recent Advances and Insights at the Interface
    Olalekan H. Usman, Jerome Irianto · 2023 · Current cancer research
85. Perfil molecular das vias de sinalização dos carcinomas de pulmão de células não pequenas por Sequenciamento de Nova Geração (NGS) com ênfase à Transição Epitélio Mesenquimal (EMT)
    Juliana Rodrigues Machado Rúgolo · 2023 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
86. Analysis of EGFR Gene Mutations in Lung Adenocarcinoma in Karamay, Xinjiang
    Yuhua Ma, Yuanxin Li, Min Jiang, Jing Gao, Yining Lai, Kamila Kulaixijiang, Min Zhu, Fei Liang · 2023 · Oncology and Translational Medicine
87. Búsqueda de biomarcadores pronósticos y terapéuticos en el carcinoma pulmonar de células escamosas. Correlación clínico-patológica
    Luís Miguel Chinchilla-Tábora · 2023
88. Anticancer activity of Araguspongine C via inducing apoptosis, and inhibition of oxidative stress, inflammation, and EGFR‐TK in human lung cancer cells: An in vitro and in vivo study
    Zhe Li, Hongjiang Yu, Shaik Althaf Hussain, Rui Yang · 2024 · Journal of Biochemical and Molecular Toxicology
89. Anti-lung cancer activity of lotusine in non-small cell lung cancer HCC827 via reducing proliferation, oxidative stress, induction of apoptosis, and G0/G1 cell cycle arrest via suppressing EGFR-Akt-ERK signalling
    Yuanmin Lan, Jing Sun, Jiqing Xu, Xiaoying Chen · 2025 · In Vitro Cellular & Developmental Biology - Animal
90. Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report
    Bradley Steiner, Amanda Edmond, Monica Camou, Taylor Praska, Jiaxin Niu · 2025 · Reports — Medical Cases Images and Videos
91. A Comparative Review of Methods for Detecting Epidermal Growth Factor Receptor Mutations in Cell-free DNA from Lung Cancer Patients
    Sepideh Shohani, Mahmood Barati, Arshad Hosseini · 2025 · Current Molecular Medicine
92. Additional file 1 of Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
    Kang, Da Hyun, Jung, Sung Soo, Yeo, Min-Kyung, Lee, Da Hye, Geon Yoo, Sang Yeon Cho, Oh, In-Jae, Kim, Ju-Ock, Hee Sun Park, Chung, Chaeuk et al. · 2020 · Figshare
93. Rôle du facteur de transcription ZEB1 dans la progression et chimiorésistance du cholangiocarcinome
    Cindy Lobe · 2019
94. Innovative Biotechnology-Based Healthcare Products
    Rohan Sathwik Patteti, Nishu Goyal · 2026 · Springer handbooks
95. Prevalence and profile of EGFR mutations in NSCLC: Insights from an Eastern Indian cohort
    Yugosmita Patra, Pragyan Lisha Panda, Pranati Mohanty, Gitanjali Nayak, Itishree Rana, Pratiksha Mishra · 2026 · South Asian Journal of Cancer
96. Comparative profiling of osimertinib and fourth-generation EGFR inhibitors on EGFR-mutant proteins and cell lines
    Janneke J. T. M. Melis, Kirsten J. Kevenaar, Jacob Ytsma, Daphne J. F. Kluitmans, Janneke M. van den End, Jeffrey J. Kooijman, Jonne L. K. van Eck, Esmee van den Bossche, Jeroen A.D.M. de Roos, Yusuke Kawase et al. · 2026 · Frontiers in Oncology
97. In vitro cellular uptake, release, and cytotoxicity of pH-Responsive albumin-functionalized carbonate apatite nanocarriers for enhanced afatinib delivery in EGFR-mutant non-small cell lung cancer
    Nian N. N. Maarof, Azren Aida Asmawi, Emilia Abdulmalek, Sharida Fakurazi, Mohd Basyaruddin Abdul Rahman · 2026 · Journal of Drug Delivery Science and Technology
98. BindingDB Entry 50005631: Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR).
    BindingDB · 2020 · UC San Diego